Stephens Inc. AR Trims Holdings in Becton, Dickinson and Company (BDX)

Stephens Inc. AR reduced its holdings in Becton, Dickinson and Company (NYSE:BDX) by 27.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,255 shares of the medical instruments supplier’s stock after selling 3,136 shares during the period. Stephens Inc. AR’s holdings in Becton, Dickinson and were worth $1,611,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of BDX. Almanack Investment Partners LLC. bought a new stake in shares of Becton, Dickinson and during the first quarter valued at approximately $105,000. Parkside Financial Bank & Trust boosted its stake in Becton, Dickinson and by 1.4% in the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 9 shares in the last quarter. QCI Asset Management Inc. NY boosted its stake in Becton, Dickinson and by 9.2% in the 1st quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock valued at $130,000 after buying an additional 60 shares in the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in Becton, Dickinson and by 55.8% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after buying an additional 240 shares in the last quarter. Finally, Financial Architects Inc boosted its stake in Becton, Dickinson and by 8.0% in the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after buying an additional 54 shares in the last quarter. 87.12% of the stock is currently owned by institutional investors.

In related news, EVP Linda M. Tharby sold 4,695 shares of Becton, Dickinson and stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total transaction of $941,253.60. Following the transaction, the executive vice president now owns 18,670 shares in the company, valued at approximately $3,742,961.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of Becton, Dickinson and stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares in the company, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. Insiders have sold a total of 75,904 shares of company stock worth $15,242,688 in the last quarter. Corporate insiders own 1.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Stephens Inc. AR Trims Holdings in Becton, Dickinson and Company (BDX)” was published by BBNS and is the sole property of of BBNS. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://baseballnewssource.com/markets/becton-dickinson-and-company-bdx-holdings-reduced-by-stephens-inc-ar/1700967.html.

Becton, Dickinson and Company (NYSE BDX) opened at 203.07 on Wednesday. The company has a market cap of $46.21 billion, a price-to-earnings ratio of 58.81 and a beta of 1.05. The stock’s 50 day moving average price is $197.13 and its 200-day moving average price is $193.13. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. The business had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm’s revenue was down 5.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.35 EPS. On average, equities research analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 29th. Stockholders of record on Friday, September 8th were paid a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a dividend yield of 1.44%. The ex-dividend date was Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

BDX has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Becton, Dickinson and from a “hold” rating to a “sell” rating in a research note on Monday, October 9th. Raymond James Financial, Inc. raised Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and cut their price target for the company from $210.00 to $180.00 in a research note on Friday, June 30th. BidaskClub raised Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. Wells Fargo & Company initiated coverage on Becton, Dickinson and in a research note on Friday, September 22nd. They set an “outperform” rating and a $225.00 price target on the stock. Finally, Cowen and Company reiterated a “buy” rating and issued a $230.00 price objective on shares of Becton, Dickinson and in a report on Monday, August 14th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Becton, Dickinson and presently has an average rating of “Buy” and a consensus target price of $200.93.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with our FREE daily email newsletter.

 


Latest News

Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Red Sox Beat Houston Sunday to Avoid Elimination
Red Sox Beat Houston Sunday to Avoid Elimination


Leave a Reply

 
© 2006-2017 BBNS.